We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Chesapeake to Repay Term Loan Through Senior Notes Offering
Read MoreHide Full Article
Chesapeake Energy Corporation recently announced that the aggregate principal amount of the notes, being offered, is estimated at $1.25 billion. The company has priced all the senior notes on par.
The notes offering will likely close on Sep 27, subject to customary closing conditions. Investors should know that the series of notes, with principal amount of $850 million, will likely carry an interest rate of 7%. The notes are expected to mature by 2024.
The other series, with $400 million principal, is anticipated to carry a 7.50% interest rate. The notes will mature in 2026. The offering’s net proceeds will likely be utilized for repaying the company’s outstanding secured term loan, slated to mature in 2021. The remaining amount, if any, will be allocated for normal corporate activities.
It is to be noted that along with the net offering proceeds, the company will use cash balances and debts under revolving credit facility for paying back the term loan.
The notes offering to repay another borrowing reflect the company’s debt laden balance sheet. In fact, the debt-to-capitalization ratio of the company is 106.02%, significantly higher than the industry’s 45.52%.
Headquartered in Oklahoma City, OK, Chesapeake is primarily engaged in exploiting onshore unconventional oil and gas resources. The company surpassed the Zacks Consensus Estimate for earnings in all the prior four quarters, the average positive earnings surprise being 20.8%.
However, the company’s pricing chart is not impressive. Over the past year, Chesapeake has lost 0.5% against the 11.5% collective gain of the stocks belonging to the industry.
Currently, the stock carries a Zacks Rank #3 (Hold). Meanwhile, a few better-ranked players in the energy sector include Shell Midstream Partners LP , Petroleo Brasileiro S.A. or Petrobras (PBR - Free Report) and Denbury Resources Inc. . Shell Midstream Partners and Petrobras sport a Zacks Rank #1 (Strong Buy), while Denbury carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Shell Midstream Partners has an average positive earnings surprise of 7.9% for the last four quarters.
Petrobras’ bottom line beat the Zacks Consensus Estimate in three of the trailing four quarters, the average beat being 10.4%.
Denbury beat the Zacks Consensus Estimate for earnings in each of the prior four quarters, the average positive surprise being 162.9%.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
Chesapeake to Repay Term Loan Through Senior Notes Offering
Chesapeake Energy Corporation recently announced that the aggregate principal amount of the notes, being offered, is estimated at $1.25 billion. The company has priced all the senior notes on par.
The notes offering will likely close on Sep 27, subject to customary closing conditions. Investors should know that the series of notes, with principal amount of $850 million, will likely carry an interest rate of 7%. The notes are expected to mature by 2024.
The other series, with $400 million principal, is anticipated to carry a 7.50% interest rate. The notes will mature in 2026. The offering’s net proceeds will likely be utilized for repaying the company’s outstanding secured term loan, slated to mature in 2021. The remaining amount, if any, will be allocated for normal corporate activities.
It is to be noted that along with the net offering proceeds, the company will use cash balances and debts under revolving credit facility for paying back the term loan.
The notes offering to repay another borrowing reflect the company’s debt laden balance sheet. In fact, the debt-to-capitalization ratio of the company is 106.02%, significantly higher than the industry’s 45.52%.
Headquartered in Oklahoma City, OK, Chesapeake is primarily engaged in exploiting onshore unconventional oil and gas resources. The company surpassed the Zacks Consensus Estimate for earnings in all the prior four quarters, the average positive earnings surprise being 20.8%.
However, the company’s pricing chart is not impressive. Over the past year, Chesapeake has lost 0.5% against the 11.5% collective gain of the stocks belonging to the industry.
Currently, the stock carries a Zacks Rank #3 (Hold). Meanwhile, a few better-ranked players in the energy sector include Shell Midstream Partners LP , Petroleo Brasileiro S.A. or Petrobras (PBR - Free Report) and Denbury Resources Inc. . Shell Midstream Partners and Petrobras sport a Zacks Rank #1 (Strong Buy), while Denbury carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Shell Midstream Partners has an average positive earnings surprise of 7.9% for the last four quarters.
Petrobras’ bottom line beat the Zacks Consensus Estimate in three of the trailing four quarters, the average beat being 10.4%.
Denbury beat the Zacks Consensus Estimate for earnings in each of the prior four quarters, the average positive surprise being 162.9%.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>